Injectable Drug Industry Analysis in North America
Analyzing Injectable Drug Demand Outlook in North America by Antibiotics and Antivirals, 2024 to 2034
Escalating Prevalence of Chronic Diseases like Cancer and Diabetes and Growing Popularity of Biologics Opening Growth Windows for Injectable Drug Industry in North America
North America Injectable Drug Industry Outlook from 2024 to 2034
Recording a y-o-y growth of 8.5%, injectable drug sales in North America are forecast to total US$ 209.2 billion in 2024. A healthy CAGR of 6.9% is on the horizon for the North America injectable drug industry, with total revenue reaching a staggering US$ 407.2 billion by 2034.
Analgesics remain the top-selling injectable drugs across North America, owing to their high adoption in pain management. The target segment is forecast to record a CAGR of 8.8% from 2024 to 2034.
North America Injectable Drug Industry Forecast
Attributes
Key Insights
Base Value in 2023
US$ 192.8 billion
North America Injectable Drug Industry Size in 2024
US$ 209.2 billion
North America Injectable Drug Industry Value in 2034
US$ 407.2 billion
Value CAGR (2024 to 2034)
6.9%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
North America Injectable Drug Industry Overview
Injectable drugs such as antibiotics, antivirals, analgesics, corticosteroids, vasodilators, antipsychotics, and opioids are witnessing high demand across North America. This can be attributed to rising incidence of chronic disease and quick and effective action of injectables.
Injectable drugs are becoming versatile and effective means of delivering medication quickly. Their fast action, enhanced bioavailability, and higher effectiveness make them popular in managing a wide variety of medical conditions.
Healthcare professionals prefer injectable drugs, especially in complex cases, as they allow for accurate dosing and rapid biological response. Growing popularity of injectable drugs for treating chronic infections, diabetes, cancer, and pain will propel sales growth.
The rise of biologics like insulin, monoclonal antibodies, and gene therapies is opening new growth windows for injectable drug companies. Similarly, rising popularity of self-injectables due to their convenience will benefit the injectable drug industry in North America.
Sales remain particularly high for analgesic drugs owing to their adoption for pain management. These medications quickly and effectively relieve severe pain, making them highly sought-after in the region.
There are a handful of sterile injectable manufacturers with limited production capacity. Also, the manufacturing process is complicated and has large lead time. These factors have made the injectable drug industry prone to shortage.
As per the survey conducted by ASHP in March 2022, there was a shortage of certain important injectable drugs. The key finding of the survey showed prefilled 50% dextrose syringes, 0.9% saline syringes or vials, local anesthetic vials (with or without epinephrine), and prefilled epinephrine syringes were severely impacted by the shortage along with other medications.
To address this shortage, manufacturers are focusing on enhancing their production capacity. They are also collaborating with contract manufacturing organizations (CMOs) to reduce costs and save their time.
Historical Performance Vs. Future North America Injectable Drug Demand Outlook
Sales of injectable drugs in North America increased at a CAGR of 5.9% from 2019 to 2023. Total revenue at the end of 2034 reached around US$ 192.8 billion. Between 2024 and 2034, injectable drug demand in the region is forecast to surge at 6.9% CAGR.
Growing awareness about the advantages of injectables is a key factor propelling demand. Injectable drugs offer multiple benefits, including fast action and high effectiveness. This is making them popular among healthcare professionals and patients.
Another contributor to the industry expansion is the continuous drug approval and product launch. Top injectable drug manufacturers are constantly introducing new products targeting various therapeutic areas.
In 2022, the United States Food & Drug Administration (US FDA) approved over 100 injectable drugs. Also, in April 2023, Endo Pharmaceutical announced the launch of Argatroban injection through Premier's ProRx private-label program.
In January 2022, Hikma launched the diazepam injection, USP, in a single-dose prefilled syringe. This shows the harmony between the strategic moves adopted by companies and the supporting regulatory process, which is fueling the injectable drug industry.
Find your sweet spots for generating winning opportunities in this market.
Factors Boosting Growth of Injectable Drug Industry in North America
Rising trend of outsourcing drug development processes is emerging as a key factor boosting the industry. Injectable pharmaceutical companies are shifting toward contract development and manufacturing organizations for numerous reasons.
Outsourcing manufacturing allows companies to increase their production capacity and tackle the drug shortage within the industry. It also reduces the investment required for facility and maintaining the team of experts.
The growing adoption of generic injectable drugs is another factor boosting injectable drug industry growth in North America. According to the US FDA, 91% of all prescriptions are generic drugs in the United States.
In 2017, the FDA granted approval for 80 new orphan indications and further 53 approvals in 2020. Hence, the shift toward outsourcing manufacturing activities, increased adoption of generic drugs, and new approval of orphan drugs will create lucrative growth prospects for manufacturers.
Factors Limiting North America Injectable Drug Industry Growth
Despite the significant opportunity for injectable drug industry, the high operational costs of injectable drugs act as a restraint for the industry. These medications require complex equipment for manufacturing. This leads to high operating costs and high debt levels due to the purchase or rent-to-lease of capital equipment.
The elevated expenses can create challenges for patients, healthcare providers, and healthcare systems, potentially leading to restricted access and utilization of injectable therapies. Additionally, high drug prices may result in increased financial burdens on individuals and healthcare budgets, influencing treatment decisions and industry expansion.
The regulatory cost burden is also high as the United States Food and Drug Administration (FDA) mandates to maintain a high degree of care in not only manufacturing but also packaging, storage, and distribution. Some areas of high cost include maintaining sterility from bacterial and fungal contamination and stability issues (crystallization). This can limit industry expansion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Comparative View of Adjacent North America Injectable Drug Industry
In the section below, the North America injectable drug industry is compared to the global injectable drug industry and the pain therapeutic injectable industry based on growth factors and key trends. This will help players to get a better understanding of the industry scenario.
The insulin management system industry is set to record a robust CAGR than the other two industries. This can be attributed to rising incidence of chronic diseases and development of advanced drug delivery systems like autoinjectors and prefilled syringes.
North America Injectable Drug Industry Analysis:
Attributes
North America Injectable Drug Sales Forecast
CAGR (2024 to 2034)
6.9%
Growth Factor
Escalating popularity of injectables for treating diseases like cancer and diabetes due to their quick action is augmenting industry growth.
Trends in North America Injectable Drug Industry
Rising interest in biologics & biosimilars and development of self-injectable drugs are key trends shaping the injectable drug industry in North America.
Global Injectable Drug Industry Analysis:
Attributes
Global Injectable Drug Demand Outlook
CAGR (2024 to 2034)
5.8%
Growth Factor
Growing prevalence of chronic and infectious diseases is providing impetus for the growth of injectable drug industry.
Key Trends in the Global Injectable Drug Industry
New product launches and approvals will lead to industry expansion.
Pain Therapeutic Injectable Industry Outlook:
Attributes
Pain Therapeutic Injectable Sales Outlook
CAGR (2024 to 2034)
4.5%
Growth Factor
Rising prevalence of chronic pain conditions, such as cancer pain, arthritis, and lower back pain, is forecast to boost sales growth.
Pain Therapeutic Injection Industry Trends
Key trends include rising popularity of long-acting pain therapeutics, adoption of biologic pain therapeutics, and innovations in drug delivery systems.
Country-wise Insights
The table below shows the estimated growth rates of different nations across North America. Canada is set to witness high injectable drug consumption, recording a CAGR of 8.7% through 2034.
Growth Outlook by Key Countries
Countries
Value CAGR
United States
6.8%
Canada
8.7%
Rising Prevalence of Chronic Diseases Propelling Sales in the United States
The United States injectable drug industry has a bright future, with total valuation reaching US$ 202.88 billion in 2024. Emerging trends indicate injectable drug sales to rise at around 6.8% across the United States through 2034.
Growing incidence of chronic diseases, such as diabetes and cancer, is a key factor providing impetus for sales growth. Subsequently, escalating popularity of biologics, especially insulin and other cancer treatments, administered through injection will boost sales.
The United States has a well-established healthcare infrastructure which establishes its dominance in North America. According to the American Hospital Association (AHA), there are around 916,752 staffed beds in all United States hospitals and about 33,679,935 admissions.
The growing hospital admissions and high prevalence of chronic diseases are leading to increased use of injectable drugs, thereby pushing sales growth. Strong presence of top pharmaceutical giants is also improving the United States injectable drug industry share.
Canada to Present Lucrative Growth Opportunities to Injectable Drug Companies
Canada is emerging as a highly remunerative pocket for injectable drug manufacturers and distributors. A robust CAGR of 8.7% has been predicted for Canada's injectable drug industry between 2024 and 2034.
Canada has a stringent regulatory framework, and there is growing adoption of biologics. These complex molecules, often administered via injection, offer targeted therapies for various diseases. This is providing impetus for the growth of injectable drug industry in the country.
The ongoing innovations in drug delivery systems and rising burden of diseases are other factors behind the rising sales of injectable drugs. Similarly, favorable government support will aid in the expansion of the target industry.
Category-wise Insights
The section covers all the leading segments of North America’s injectable drug industry. By drug class, the analgesics segment is projected to witness a CAGR of 8.8% through 2034. In terms of route of administration, the intravenous (IV) injections segment is likely to showcase a 6.0% CAGR through 2034.
Analgesics Remain Highly Sought-after Drugs in North America
Growth Outlook by Drug Class
Drug Class
Value CAGR
Antibiotics
5.1%
Antivirals
7.0%
Antifungal
9.4%
Antibacterial
4.8%
Analgesics
8.8%
Antipsychotic
7.6%
Opioids
4.1%
Local and General Anesthetics
7.8%
Anticoagulants
9.0%
Anticovasculants
7.7%
Muscle Relaxant
8.3%
Antihistamines
7.2%
Corticosteroids
4.4%
Calcium
6.1%
Cardiotonic
8.0%
Sympathomimetic
9.2%
Hormonal Contraceptive
4.7%
Intravenous Infusion
9.1%
Vasodilator
5.7%
Beta-blockers
4.6%
Vitamins
7.3%
Antiemetic
8.4%
Proton-Pump Inhibitors (PPIs)
4.2%
Chemotherapy Drugs
8.4%
Others
5.2%
Injectable analgesic drugs are in high demand across North America. This is attributable to growing need for pain management across different therapeutic areas. As per the latest analysis, the analgesics segment will display a CAGR of 8.8%, accounting for a revenue share of 12.6% in 2034.
Analgesics drugs like paracetamol, opioids, aspirin, and NSAIDS are the first line to treat many cases of pain management. Injectable analgesics are especially gaining popularity in North America due to their ability to quickly and effectively relieve severe or acute pain.
Intravenous Injections Remain Preferred Route of Administration
Growth Outlook by Route of Administration
Route of Administration
Value CAGR
Intravenous (IV) Injections
6.0%
Intramuscular (IM) Injections
7.7%
Subcutaneous (SC) Injections
8.8%
Intravenous injections remain the gold standard route of administration in North America. This is due to its multiple benefits, including fast drug delivery and precision. This route of administration is ideal in situations where speed and accuracy are significant.
As per the latest report, the intravenous injections segment will continue to retain its dominance in North America, holding a share of 47.9% in 2024. Further, a CAGR of 6.0% is on the cards for the target segment.
Intravenous administration is a widely preferred route of administration in hospitals and by major surgeons. This is because it offers predictable bioavailability and precise dosage delivery.
In chronic cases where quick response is required, IV route is used. IV medications have the tendency to deliver life-saving drugs quickly and effectively in situations like heart attack, shock, and chronic infection.
Injectable Drugs Gaining High Prominence in Cancer Treatment
Growth Outlook By Therapeutic Area
Therapeutic Area
Value CAGR
Pain Management
5.4%
Cardiovascular Disease
7.9%
Infectious Disease
5.9%
Allergy
6.8%
Gastrointestinal Disease
6.5%
Nutrition Deficiency
4.1%
Hematology Disorders
5.0%
Gynecology
7.3%
Cancer
9.8%
Injectable drug usage is rising rapidly in cancer treatments due to their fast and quick action. Courtesy of this, the target segment will probably thrive at 9.8% CAGR between 2024 and 2034.
Growing incidence of cancer in North America will lead to higher demand for cancer treatments, creating growth opportunities for injectable drug manufacturers. Similarly, rising importance of injectable drugs for cancer is set to accelerating segment growth.
According to the World Health Organization (WHO), the cancer burden is escalating in North America and other regions. This, in turn, is propelling demand for chemotherapy and other cancer treatments that use injectable drugs.
Chemotherapy is the most widely used treatment option for cancer patients. It involves administration of chemical agents through IV route to target cancerous cells. Hence, growing cancer prevalence and rise in chemotherapy will continue to give the cancer segment a slight edge over other therapeutic areas.
Competitive Landscape
Leading manufacturers of injectable drugs in North America are constantly investing in research and development to explore new drugs targeting various therapeutic areas. They are also exploring new drug delivery systems, including self-injectable options, as well as developing targeted therapies and biologics to stay ahead of the competition.
Several injectable drug companies are partnering and collaborating with contract manufacturing organizations (CMOs) to reduce costs and save time. Similarly, the North America injectable drug industry is witnessing strategies like acquisitions, distribution agreements, and mergers as players look to push their expertise and footprint.
Recent Developments in North America Injectable Drug Industry
In April 2023, Teva Pharmaceuticals MedinCell announced FDA approval of UZEDY extended-release injectable suspension to treat schizophrenia in adults.
In January 2020, Merck established a Strategic Oncology Collaboration with Taiho and Astex.
In January 2022, Sanofi and Exscientia collaborated to develop AI-driven pipeline of precision-engineered medicines.
In October 2022, Pfizer Inc. completed acquisition of Global Blood Therapeutics, Inc.
Key Coverage in North America Injectable Drug Industry Research Report
Adjacent Study on Global Sterile Injectable Drugs Market, North America Drug Delivery Market, Lyophilized Injectable Drugs, and Injectable Drug Delivery Technology Market
Detailed North America Pharmaceutical Market Analysis
Recently Approved Injectable Drugs in North America
Popular Sterile Injectable Drugs across North America
Factors Encouraging Adoption of Self-injectable Drugs
Expected Injectable Drug Delivery Market Size
Current Small Molecule Injectable Drugs Market Size vs. large Molecules Injectable Drugs Market Size
Injectable Drug Delivery Devices Global Market Report
North America Injectable Drug Industry Report Scope
Attribute
Details
Industry Value in 2024
US$ 209.2 billion
Industry Size in 2034
US$ 407.2 billion
Growth Rate (2024 to 2034)
6.9% CAGR
Forecast Period
2024 to 2034
Historical Data Available for
2019 to 2023
Industry Analysis
US$ billion for Value
Key Regions Covered
North America
Key Countries Covered
United States, Canada, and Mexico
Key Industry Segments Covered
Drug Class, Route of Administration, Therapeutic Area, Molecule Type, and Distribution Channel.
Key Companies Profiled
Pfizer Inc.
GlaxoSmithKline Plc.
Sanofi
Merck & Co., Inc.
Eli Lilly and Company
Boehringer Ingelheim International GmbH
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Bayer AG
Amgen Inc.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Eisai Co., Ltd.
Sandoz (Novartis AG)
Teva Pharmaceutical Industries Ltd.
Cipla Ltd.
Sun Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals
Hikma Pharmaceuticals PLC
Viatris Inc. (Mylan N.V)
Endo International (Par Pharmaceutical )
Aspen Pharmacare
Aurobindo Pharma
Report Coverage
Industry Forecast, Competition Intelligence, DROT Analysis, Industry Dynamics and Challenges, Strategic Growth Initiatives
North America Injectable Drug Industry Segmentation
By Drug Class:
Antibiotics
Antivirals
Antifungal
Antibacterial
Analgesics
Antipsychotic
Opioids
Local and General Anesthetics
Anticoagulants
Anticovasculants
Muscle Relaxant
Antihistamines
Corticosteroids
Calcium
Cardiotonic
Sympathomimetic
Hormonal Contraceptive
Intravenous Infusion
Vasodilator
Beta-blockers
Vitamins
Antiemetic
Proton-Pump Inhibitors (PPIs)
Chemotherapy Drugs
Others
By Route of Administration:
Intravenous (IV) Injections
Intramuscular (IM) Injections
Subcutaneous (SC) Injections
By Therapeutic Area:
Pain Management
Cardiovascular Disease
Infectious Disease
Allergy
Gastrointestinal Disease
Nutrition Deficiency
Hematology Disorders
Gynecology
Cancer
By Molecule Type:
Small Molecules
Large Molecules
By Distribution Channel:
Hospitals
Clinics
Ambulatory Surgical Centers
Long Term Care Facilities
Retail Pharmacy Chains
Online Pharmacies/Mail Order Pharmacies
By Country:
United States
Canada
Frequently Asked Questions
How big is the North America injectable drug industry?
The North America industry value is set to total US$ 209.2 billion in 2024.
What is the growth projection for North America industry?
The North America industry size is forecast to reach US$ 407.2 billion by 2034.
What is the demand outlook for injectable drugs?
Injectable drug demand in North America is set to rise at 6.9% CAGR.
Which is the most popular drug class in North America?
With a 10.8% value share, analgesics remain a popular drug class.
What was the historical CAGR for the North America industry?
The North America industry increased at a 5.9% CAGR from 2019 to 2023.
How big is the injectable industry in the United States?
The United States injectable drug industry size reached US$ 187.06 billion in 2023.
Table of Content
1. Executive Summary
1.1. Industry Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Industry Overview
2.1. Industry Coverage / Taxonomy
2.2. Industry Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Industry Trends
3.1. Key Trends Impacting the Industry
3.2. Development/Innovation Trends
3.3. Industry Trends
4. Value Added Insights
4.1. Product Adoption/ Usage Analysis
4.2. Disease Epidemiology
4.3. List of Competitive Generic Therapy Approvals
4.4. List of Approved Drug in United States
4.5. Pipeline Assessment
4.6. Porter’s Analysis
4.7. PESTEL Analysis
4.8. Supply Chain Analysis
4.9. Regulatory Landscape
4.10. Reimbursement Guidelines
4.11. Parent Industry Analysis
5. Industry Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global R&D Funding, by Region
5.1.3. Pharmaceutical Spending, by Key Countries
5.2. Forecast Factors - Relevance & Impact
5.2.1. Historical Growth of Key Players
5.2.2. Industry Consolidation Activities
5.2.3. Increasing FDA Approvals
5.2.4. Rising Prevalence of Cancer and Cardiovascular Diseases
5.2.5. Increasing Adoption of
5.2.6. Rising Demand for Small Molecule Injectable for Pain Management
5.2.7. Cost Effectiveness of
5.2.8. Increasing Research & Development
5.2.9. Regulatory Framework
5.2.10. Key Strategic Developments By Industry Players
5.3. Industry Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Industry Demand Value or Size (US$ billion) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Industry Value (US$ billion) Analysis, 2019 to 2023
6.2. Current and Future Industry Value (US$ billion) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
6.3. Revenue Opportunity Scenario
7. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Industry Size (US$ billion) Analysis By Drug Class, 2019 to 2023
7.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Drug Class, 2024 to 2034
7.3.1. Antibiotics
7.3.2. Antivirals
7.3.3. Antifungal
7.3.4. Antibacterial
7.3.5. Analgesics
7.3.6. Antipsychotic
7.3.7. Opioids
7.3.8. Local and General Anesthetics
7.3.9. Anticoagulants
7.3.10. Anticovasculants
7.3.11. Muscle Relaxant
7.3.12. Antihistamines
7.3.13. Corticosteroids
7.3.14. Calcium
7.3.15. Cardiotonic
7.3.16. Sympathomimetic
7.3.17. Hormonal Contraceptive
7.3.18. Intravenous Infusion
7.3.19. Vasodilator
7.3.20. Beta-blockers
7.3.21. Vitamins
7.3.22. Antiemetic
7.3.23. Proton-Pump Inhibitors (PPIs)
7.3.24. Chemotherapy Drug
7.3.25. Others
7.4. Industry Attractiveness Analysis By Drug Class
8. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Industry Size (US$ billion) By Route of Administration, 2019 to 2023
8.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Route of Administration, 2024 to 2034
8.3.1. Intravenous (IV) injections
8.3.2. Intramuscular (IM) injections
8.3.3. Subcutaneous (SC) injections
8.4. Industry Attractiveness Analysis By Route of Administration
9. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
9.1. Introduction / Key Findings
9.2. Historical Industry Size (US$ billion) By Therapeutic Area, 2019 to 2023
9.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Therapeutic Area, 2024 to 2034
9.3.1. Pain Management
9.3.2. Cardiovascular Disease
9.3.3. Infectious Disease
9.3.4. Allergy
9.3.5. Gastrointestinal Disease
9.3.6. Nutrition Deficiency
9.3.7. Hematology Disorders
9.3.8. Gynecology
9.3.9. Cancer
9.4. Industry Attractiveness Analysis By Therapeutic Area
10. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Molecule Type
10.1. Introduction / Key Findings
10.2. Historical Industry Size (US$ billion) By Molecule Type, 2019 to 2023
10.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Molecule Type, 2024 to 2034
10.3.1. Small Molecules
10.3.2. Large Molecules
10.4. Industry Attractiveness Analysis By Molecule Type
11. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Industry Size (US$ billion) By Distribution Channel, 2019 to 2023
11.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Distribution Channel, 2024 to 2034
11.3.1. Hospital
11.3.2. Clinics
11.3.3. Ambulatory Surgical Centers
11.3.4. Long Term Care Facilities
11.3.5. Retail Pharmacy Chains
11.3.6. Online Pharmacies/Mail Order Pharmacies
11.4. Industry Attractiveness Analysis By Distribution Channel
12. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Introduction
12.2. Historical Industry Size (US$ billion) Trend Analysis by Country, 2019 to 2023
12.3. Current Industry Size (US$ billion) Analysis and Forecast by Country, 2024 to 2034
12.3.1. United States
12.3.2. Canada
12.4. Industry Attractiveness Analysis By Country
13. United States Industry Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Industry Size (US$ billion) Trend Analysis by Industry Taxonomy, 2019 to 2023
13.3. Current and Future Industry Size (US$ billion) Analysis and Forecast by Industry Taxonomy, 2024 to 2034
13.3.1. By Drug Class
13.3.2. By Route of Administration
13.3.3. By Therapeutic Area
13.3.4. By Molecule Type
13.3.5. By Distribution Channel
13.4. Industry Attractiveness Analysis
13.4.1. By Drug Class
13.4.2. By Route of Administration
13.4.3. By Therapeutic Area
13.4.4. By Molecule Type
13.4.5. By Distribution Channel
13.5. Drivers and Restraints - Impact Analysis
14. Canada Industry Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Industry Size (US$ billion) Trend Analysis by Industry Taxonomy, 2019 to 2023
14.3. Current and Future Industry Size (US$ billion) Analysis and Forecast by Industry Taxonomy, 2024 to 2034
14.3.1. By Drug Class
14.3.2. By Route of Administration
14.3.3. By Therapeutic Area
14.3.4. By Molecule Type
14.3.5. By Distribution Channel
14.4. Industry Attractiveness Analysis
14.4.1. By Drug Class
14.4.2. By Route of Administration
14.4.3. By Therapeutic Area
14.4.4. By Molecule Type
14.4.5. By Distribution Channel
14.5. Drivers and Restraints - Impact Analysis
15. Industry Structure Analysis
15.1. Industry Analysis by Tier of Companies
15.2. Industry Share Analysis of Top Players (%)
15.3. Industry Presence Analysis
16. Competition Analysis
16.1. Competition Dashboard
16.2. Branding and Promotional Strategies by Industry Players
16.3. Key Development Analysis
16.4. Competition Benchmarking
16.5. Competition Deep Dive
16.5.1. Pfizer Inc.
16.5.1.1. Overview
16.5.1.2. Product Portfolio
16.5.1.3. Pipeline Products
16.5.1.4. Key Financials
16.5.1.5. SWOT Analysis
16.5.1.6. Key Developments
16.5.1.7. Sales Footprint
16.5.1.8. Strategy Overview
16.5.1.8.1. Industrying Strategy
16.5.1.8.2. Product Strategy
16.5.1.8.3. Channel Strategy
16.5.2. GlaxoSmithKline Plc.
16.5.3. Sanofi
16.5.4. Merck & Co., Inc.
16.5.5. Eli Lilly and Company
16.5.6. Boehringer Ingelheim International GmbH
16.5.7. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
16.5.8. Bayer AG
16.5.9. Amgen Inc.
16.5.10. Novo Nordisk A/S
16.5.11. Takeda Pharmaceutical Company Limited
16.5.12. Eisai Co., Ltd.
16.5.13. Sandoz (Novartis AG)
16.5.14. Teva Pharmaceutical Industries Ltd.
16.5.15. Cipla Ltd.
16.5.16. Sun Pharmaceutical Industries Ltd.
16.5.17. Lupin Pharmaceuticals
16.5.18. Hikma Pharmaceuticals PLC
16.5.19. Viatris Inc. (Mylan N.V)
16.5.20. Endo International (Par Pharmaceutical)
16.5.21. Aspen Pharmacare
16.5.22. Aurobindo Pharma
17. Assumptions and Acronyms Used18. Research Methodology
List of Tables
Table 01: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 02: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 03: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapeutic Area
Table 04: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Molecule Type
Table 05: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 06: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 07: United States Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 08: United States Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 09: United States Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapeutic Area
Table 10: United States Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Molecule Type
Table 11: United States Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Table 12: Canada Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Table 13: Canada Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Table 14: Canada Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapeutic Area
Table 15: Canada Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Molecule Type
Table 16: Canada Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
List of Charts
Figure 01: Industry Value Share by Drug Class 2024 (E)
Figure 02: Industry Value Share by Route of Administration 2024 (E)
Figure 03: Industry Split by Therapeutic Area 2024 (E)
Figure 04: Industry Value Share by Molecule Type 2024 (E)
Figure 05: Industry Split by Distribution Channel 2024 (E)
Figure 06: Industry Split by Country 2024 (E)
Figure 07: Industry Historical Industry Value, 2019 to 2023
Figure 08: Industry Value (US$ billion) and Y-o-Y Growth (%), 2024 to 2034
Figure 09: Industry Absolute $ Opportunity, 2024 to 2034
Figure 10: Industry Analysis by Drug Class 2024 (E) to 2034 (F)
Figure 11: Industry Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 12: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
Figure 13: Industry Analysis by Route of Administration 2024 (E) to 2034 (F)
Figure 14: Industry Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 15: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
Figure 16: Industry Analysis by Therapeutic Area 2024 (E) to 2034 (F)
Figure 17: Industry Y-o-Y Growth Projections by Therapeutic Area, 2024 to 2034
Figure 18: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapeutic Area
Figure 19: Industry Analysis by Molecule Type 2024 (E) to 2034 (F)
Figure 20: Industry Y-o-Y Growth Projections by Molecule Type, 2024 to 2034
Figure 21: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Molecule Type
Figure 22: Industry Analysis by Distribution Channel 2024 (E) to 2034 (F)
Figure 23: Industry Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 24: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
Figure 25: Industry Analysis by Region 2024 (E) to 2034 (F)
Figure 26: Industry Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 27: Industry Size (US$ billion) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
Figure 28: United States Industry Value Share by Drug Class 2024 (E)
Figure 29: United States Industry Value Share by Route of Administration 2024 (E)
Figure 30: United States Industry Split by Therapeutic Area 2024 (E)
Figure 31: United States Industry Value Share by Molecule Type 2024 (E)
Figure 32: United States Industry Split by Distribution Channel 2024 (E)
Figure 33: United States Industry Value (US$ billion) Analysis, 2019 to 2023
Figure 34: United States Industry Value (US$ billion) and Y-o-Y Growth (%), 2024 to 2034
Figure 35: United States Industry Attractiveness Analysis, by Drug Class
Figure 36: United States Industry Attractiveness Analysis, by Route of Administration
Figure 37: United States Industry Attractiveness Analysis, by Therapeutic Area
Figure 38: United States Industry Attractiveness Analysis, by Molecule Type
Figure 39: United States Industry Attractiveness Analysis, by Distribution Channel
Figure 40: Canada Industry Value Share by Drug Class 2024 (E)
Figure 41: Canada Industry Value Share by Route of Administration 2024 (E)
Figure 42: Canada Industry Split by Therapeutic Area 2024 (E)
Figure 43: Canada Industry Value Share by Molecule Type 2024 (E)
Figure 44: Canada Industry Split by Distribution Channel 2024 (E)
Figure 45: Canada Industry Value (US$ billion) Analysis, 2019 to 2023
Figure 46: Canada Industry Value (US$ billion) and Y-o-Y Growth (%), 2024 to 2034
Figure 47: Canada Industry Attractiveness Analysis, by Drug Class
Figure 48: Canada Industry Attractiveness Analysis, by Route of Administration
Figure 49: Canada Industry Attractiveness Analysis, by Therapeutic Area
Figure 50: Canada Industry Attractiveness Analysis, by Molecule Type
Figure 51: Canada Industry Attractiveness Analysis, by Distribution Channel
